UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 42

Sortiert nach

A systematic review of dimensions evaluating patient experience in chronic illness

Health and quality of life outcomes, 2019-01, Vol.17 (1), p.19-19, Article 19

2019

Volltextzugriff (PDF)

Factors Associated with Overall and Attributable Mortality in Invasive Aspergillosis

Clinical infectious diseases, 2008-11, Vol.47 (9), p.1176-1184

2008

Volltextzugriff (PDF)

Mycograb for the Treatment of Invasive Candidiasis

Clinical infectious diseases, 2006-10, Vol.43 (8), p.1083-1083

2006

Volltextzugriff (PDF)

FDG PET to Diagnose Neurolymphomatosis in a Case of Triple-Hit B-Cell Lymphoma

Clinical nuclear medicine, 2017-06, Vol.42 (6), p.458-460

2017

Volltextzugriff (PDF)

Impact of Poor Tolerance and Discontinuation of the Dexamethasone during Treatment with Lenalidomide-Dexamethasone in Relapsed and Refractory Multiple Myeloma

Blood, 2015-12, Vol.126 (23), p.5379-5379

2015

Volltextzugriff (PDF)

Antifungal combination treatment: a future perspective

International journal of antimicrobial agents, 2006-06, Vol.27, p.25-30

2006

Volltextzugriff (PDF)

Long‐term survival in post‐transplant lymphoproliferative disorders with a dose‐adjusted ACVBP regimen

British journal of haematology, 2006-09, Vol.134 (6), p.602-612

2006

Volltextzugriff (PDF)

Prognostic Factors for Survival in Invasive Aspergillosis in Adult Oncohematological Patients

Blood, 2006-11, Vol.108 (11), p.2852-2852

2006

Volltextzugriff (PDF)

Myeloid Sarcoma of the Uterine Cervix as Presentation of Acute Myeloid Leukaemia after Treatment with Low-Dose Radioiodine for Thyroid Cancer: A Case Report and Review of the Literature

Case reports in oncology, 2009-01, Vol.2 (1), p.1-6

2009

Volltextzugriff (PDF)

Four-Year Interim Analysis of Miroir, a French Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma

Blood, 2019-11, Vol.134 (Supplement_1), p.1836-1836

2019

Volltextzugriff (PDF)

Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study

Blood, 2012-03, Vol.119 (11), p.2474-2477

2012

Volltextzugriff (PDF)

Miroir: A National, Multicenter, Non-Interventional Study of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) in France

Blood, 2017-12, Vol.130, p.1848-1848

2017

Volltextzugriff (PDF)

A National, Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma: Updated Results from the Miroir Study

Blood, 2018-11, Vol.132 (Supplement 1), p.3238-3238

2018

Volltextzugriff (PDF)

Lipid formulations of amphotericin B in the management of invasive fungal infections

Therapie, 2006-05, Vol.61 (3), p.235

2006

Volltextzugriff (PDF)

MIROIR: 4-Year Interim Analysis of a Multicenter, Non-Interventional Study in France of Pomalidomide in Relapsed or Refractory Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2019-10, Vol.19 (10), p.e253-e254

2019

Volltextzugriff (PDF)

[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography for Early Evaluation of Treatment Efficacy in Advanced Non-Hodgkin Lymphoma of Uterine Corpus: A Case Report

Clinical lymphoma & myeloma, 2007-05, Vol.7 (6), p.421-424

2007

Volltextzugriff (PDF)

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients

Leukemia, 2014-03, Vol.28 (3), p.675-679

2014

Volltextzugriff (PDF)

Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014‐04 (Etoile du Nord) trial

British journal of haematology, 2019-11, Vol.187 (3), p.319-327

2019

Volltextzugriff (PDF)

Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyéLome (IFM) Krd Phase II Study

Blood, 2016-12, Vol.128 (22), p.1142-1142

2016

Volltextzugriff (PDF)

Factors Associated with Overall and Attributable Mortality in Invasive Aspergillosis. Commentary

Clinical infectious diseases, 2008, Vol.47 (9), p.1176-1187

2008

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(38)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A systematic review of dimensions evaluating patient experience in chronic illness

Factors Associated with Overall and Attributable Mortality in Invasive Aspergillosis

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Mycograb for the Treatment of Invasive Candidiasis

FDG PET to Diagnose Neurolymphomatosis in a Case of Triple-Hit B-Cell Lymphoma

Impact of Poor Tolerance and Discontinuation of the Dexamethasone during Treatment with Lenalidomide-Dexamethasone in Relapsed and Refractory Multiple Myeloma

Antifungal combination treatment: a future perspective

Long‐term survival in post‐transplant lymphoproliferative disorders with a dose‐adjusted ACVBP regimen

Maintenance Therapy by Glivec® and Pegasys® in Patients with Philadelphia Positive Acute Lymphocytic Leukemia Not Eligible for Hematopoietic Stem Cell Transplantation

Results of the AFR07 Prospective Study in De Novo Philadelphia Positive ALL Patients Aged over 55 Years: Efficacy and Safety of a Glivec® Based Induction Followed by Maintenance Therapy with Glivec® and Pegasys

Prognostic Factors for Survival in Invasive Aspergillosis in Adult Oncohematological Patients

Myeloid Sarcoma of the Uterine Cervix as Presentation of Acute Myeloid Leukaemia after Treatment with Low-Dose Radioiodine for Thyroid Cancer: A Case Report and Review of the Literature

Four-Year Interim Analysis of Miroir, a French Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma

Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study

Miroir: A National, Multicenter, Non-Interventional Study of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) in France

A National, Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma: Updated Results from the Miroir Study

Lipid formulations of amphotericin B in the management of invasive fungal infections

Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria

MIROIR: 4-Year Interim Analysis of a Multicenter, Non-Interventional Study in France of Pomalidomide in Relapsed or Refractory Multiple Myeloma

[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography for Early Evaluation of Treatment Efficacy in Advanced Non-Hodgkin Lymphoma of Uterine Corpus: A Case Report

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients

Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014‐04 (Etoile du Nord) trial

Factors Associated with Overall and Attributable Mortality in Invasive Aspergillosis. Commentary

Suchergebnisse filtern